Equity, diversity and inclusion (EDI) is a key element of excellence in research. D2R鈥檚 vision is inherently driven by principles of EDI. From its inception, D2R was designed to deliver genomic-based RNA therapies that not only advance scientific discovery but also address the specific needs of medically underserved groups, including those affected by rare and infectious diseases and cancer, and members of equity-deserving groups (EDGs). Moreover, D2R is committed to supporting the recruitment and advancement of RNA researchers from EDGs.